4-1-1997

Rapid diagnosis of dengue viremia by reverse transcriptase-polymerase chain reaction using 3'-noncoding region universal primers

T. Mirawati Sudiro  
*University of Massachusetts Medical School*

Hiroaki Ishiko  
*University of Massachusetts Medical School*

Sharone Green  
*University of Massachusetts Medical School*

*See next page for additional authors*

Follow this and additional works at: [http://escholarship.umassmed.edu/infdis_pp](http://escholarship.umassmed.edu/infdis_pp)

Part of the Immunity Commons, Immunology of Infectious Disease Commons, and the Infectious Disease Commons

Repository Citation  
Sudiro, T. Mirawati; Ishiko, Hiroaki; Green, Sharone; Nisalak, Ananda; Vaughn, David W.; Kalayanarooj, Siripen; Rothman, Alan L.; Raengsakulrach, Boonyos; Janus, Jurand; Kurane, Ichiro; and Ennis, Francis A., "Rapid diagnosis of dengue viremia by reverse transcriptase-polymerase chain reaction using 3'-noncoding region universal primers" (1997). *Infectious Diseases and Immunology Publications and Presentations*. 306.  
[http://escholarship.umassmed.edu/infdis_pp/306](http://escholarship.umassmed.edu/infdis_pp/306)

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Infectious Diseases and Immunology Publications and Presentations by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Rapid diagnosis of dengue viremia by reverse transcriptase-polymerase chain reaction using 3’-noncoding region universal primers

Authors

Keywords
dengue, viremia

Rights and Permissions
Copyright 1997 by The American Society of Tropical Medicine and Hygiene. Publisher PDF posted as allowed by the publisher’s author rights policy at http://www.ajtmh.org/oa-policy.

This article is available at eScholarship@UMMS: http://escholarship.umassmed.edu/infdis_pp/306
RAPID DIAGNOSIS OF DENGUE VIREMIA BY REVERSE TRANSCRIPTASE–POLYMERASE CHAIN REACTION USING 3'-NONCODING REGION UNIVERSAL PRIMERS

T. MIRAWATI SUDIRO, HIROAKI ISHIKO, SHARONE GREEN, DAVID W. VAUGHN, ANANDA NISALAK, SIRIPEN KALAYANAROOJ, ALAN L. ROTHMAN, BOONYOS RAENGSUKRACH, JURAND JANUS, ICHIRO KURANE, AND FRANCIS A. ENNIS

Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts; Department of Virology, U.S. Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Department of Infectious Disease, Bangkok Children's Hospital, Bangkok, Thailand

Abstract. A reverse transcriptase–polymerase chain reaction (RT-PCR) method was developed as a rapid diagnostic test of dengue viremia. To detect dengue viruses in serum or plasma specimens, a pair of universal primers was designed for use in the RT-PCR. Using these primers, the 3'-noncoding region of dengue virus types 1, 2, 3, and 4 could be amplified, but not those of other flaviviruses, such as West Nile virus, Japanese encephalitis virus, and yellow fever virus, or the alphavirus Sindbis virus. The sensitivity of the RT-PCR assay was similar to that of a quantitative fluorescent focus assay of dengue viruses in cell culture. Combining a silica method for RNA isolation and RT-PCR dengue virus could be detected in a 6-hr assay. In a preliminary study using this method, we detected dengue virus in 38 of 39 plasma specimens from which dengue virus had been isolated by mosquito inoculation. We then applied this method for detecting dengue viremia to 117 plasma samples from 62 children with acute febrile illnesses in a dengue-endemic area. We detected dengue viremia in 19 of 20 samples obtained on the day of presentation, which had been confirmed as acute dengue infection by mosquito inoculation and antibody responses. The overall sensitivity of this method was 91.4% (32 of 35; 95% confidence interval [CI] = 82.2—100%). The results from testing plasma samples from febrile nondengue patients showed a specificity of 95.4% (42 of 44; 95% CI = 89.3—100%).

Dengue virus infections can cause two forms of disease; dengue fever and dengue hemorrhagic fever. Dengue fever is a self-limited, febrile disease while dengue hemorrhagic fever can lead to life-threatening complications. Currently, the laboratory diagnosis of dengue infection depends upon isolation of dengue virus using mosquito cell cultures1 or inoculation of mosquitoes;2 or detection of anti-dengue antibody by IgM or IgG ELISA3 and/or hemagglutination inhibition assays.4 Virus isolation, which is specific and relatively sensitive early in infection, is tedious and time-consuming. Serologic tests, while simple to perform, generally require paired serum samples.3,5

The polymerase chain reaction (PCR) has the potential for sensitive, specific, and rapid detection of minute quantities of certain genetic material in clinical specimens, thus providing an attractive approach for the rapid identification of dengue infection. Several methods of reverse transcriptase (RT)-PCR using different pairs of primers for dengue viruses and different approaches for the detection of amplification products have been previously reported.5–14 However, most of the published methods require more than 24 hr for analysis. Rapid RT-PCR methods for detection of dengue viremia have been reported,5,7,10,11,13 but they have not been validated for detecting all four dengue serotypes in clinical specimens.

In this report we describe a rapid RT-PCR procedure using primers that amplify the 3'-noncoding region of dengue virus types 1, 2, 3, and 4, but not those of other flaviviruses, such as West Nile virus, Japanese encephalitis virus, and yellow fever virus, or the alphavirus Sindbis virus. Combining a silica method for RNA isolation and the RT-PCR, we could detect dengue virus in serum or plasma within 6 hr. The data presented in this paper demonstrate that this assay is sufficiently rapid and sensitive to allow early diagnosis of dengue virus infections.

MATERIALS AND METHODS

Plasma samples. Blood samples were obtained from children enrolled in a prospective study of dengue infections at the Children's Hospital, Bangkok, Thailand, and the Kamphaeng Phet Provincial Hospital, Kamphaeng Phet, Thailand, in 1994 (Kalayanarooj S and others, unpublished data). Children with fever of 72 hr or less in duration and facial flushing without obvious cause were eligible to participate in this study. Written consent was obtained from the subject's parents or guardians. The study protocol was approved by Institutional Review Boards established by the Ministry of Public Health, Thailand, the Surgeon Generals' Office of the Department of the Army, and the University of Massachusetts Medical Center. Blood was drawn daily until one day after defervescence or up to five days, and then at convalescence (8–10 days after enrollment). Blood was collected into EDTA-containing tubes; plasma was separated and stored at −70°C until the RT-PCR was performed. Each specimen collected had dengue IgM and IgG ELISA and hemagglutination inhibition assays performed. Dengue virus isolation was attempted by mosquito inoculation3 for the first three consecutive days or until virus isolation was negative on subsequent days tested (Vaughn DW and others, unpublished data). A child was diagnosed as having acute dengue infection when the serologic test results were positive, and/or dengue virus could be isolated. Control specimens used in this study were from children with febrile illness but no evidence of acute dengue infection by serologic tests with appropriately timed specimens and when mosquito inoculation test results were negative for dengue virus in their plasma.

Extraction of RNA. The RNA was extracted from human serum spiked with dengue virus or human plasma from febrile patients by a modification of the silica method that was first described by Boom and others,15 and later applied to...
M 425

RAPID RT-PCR FOR DENGUE

B. DEN: 1 CM

FFU/mI 10 10 10 10 20 200

DEN: 2 CM

FFU/mI 10 10 10 10 20 200

C. DEN: 4 M

FFU/mI 0 10 10 10 0.2 2 2 20 200

FIGURE 1. A, sequence alignment of primers ALD-1, ALD-1b, and ALD-2 with dengue (DEN) virus conserved regions. The nucleotides are numbered according to the dengue-1 genome described by Fu and others.18 Ethidium bromide-stained agarose gels for analyzing the sensitivity of the reverse transcriptase-polymerase chain reaction (RT-PCR) for dengue virus types 1 to 4 as described in the Materials and Methods. Lane C, normal human serum used as a negative control; lane M, molecular weight marker (φX174 replicative form DNA digested with Hae III). The location of the expected PCR products are shown (229 basepairs [bp], 233 bp, 227 bp, and 241 bp for dengue virus type 1, 2, 3, and 4, respectively). FRU = fluorescent focus units; FFU/Rx = fluorescent focus unit per reaction.

### A. Sense primers

<table>
<thead>
<tr>
<th>ALD-1</th>
<th>5'-AAA CCG TGC TGC TAG-3'</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALD-1b</td>
<td>5'-AAA CTG TGC AGC CTG TAG-3'</td>
</tr>
<tr>
<td>DEN-1</td>
<td>5'-AAA CCG TGC TGC CTG TAG-3'</td>
</tr>
<tr>
<td>DEN-2</td>
<td>5'------T-----A----------3'</td>
</tr>
<tr>
<td>DEN-3</td>
<td>5'-------------------------------3'</td>
</tr>
<tr>
<td>DEN-4</td>
<td>5'-------------------------------3'</td>
</tr>
</tbody>
</table>

### B. Antisense primer

<table>
<thead>
<tr>
<th>ALD-2</th>
<th>5'-TCT CTC CCA GCG TCA ATA-3'</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEN-1</td>
<td>5'-TCT CTC CCA GCG TCA ATA-3'</td>
</tr>
<tr>
<td>DEN-2</td>
<td>5'------T-----A----------3'</td>
</tr>
<tr>
<td>DEN-3</td>
<td>5'-------------------------------3'</td>
</tr>
<tr>
<td>DEN-4</td>
<td>5'-------------------------------3'</td>
</tr>
</tbody>
</table>

FIGURE 1. A, sequence alignment of primers ALD-1, ALD-1b, and ALD-2 with dengue (DEN) virus conserved regions. The nucleotides are numbered according to the dengue-1 genome described by Fu and others. Ethidium bromide-stained agarose gels for analyzing the sensitivity of the reverse transcriptase-polymerase chain reaction (RT-PCR) for dengue virus types 1 to 4 as described in the Materials and Methods. Lane C, normal human serum used as a negative control; lane M, molecular weight marker (φX174 replicative form DNA digested with Hae III). The location of the expected PCR products are shown (229 basepairs [bp], 233 bp, 227 bp, and 241 bp for dengue virus type 1, 2, 3, and 4, respectively). FRU = fluorescent focus units; FFU/Rx = fluorescent focus unit per reaction.

### Primers

We analyzed the sequence data on dengue viruses in the Genbank database (National Center for Biotechnology Information, Bethesda, MD). We chose to analyze the noncoding region that is thought to function in regulation of virus replication and that we expected to be well conserved among dengue viruses. We compared the sequences of dengue virus type 1 Singapore S275/90 strain14 (Genbank accession M87512), dengue virus type 2 New Guinea C strain17 (M29095 M19727), dengue virus type 2 Jamaica strain18 (M20558), dengue virus type 2 S1 vaccine strain19 (M19197), dengue virus type 3 Hawaii strain20 (M93130), dengue virus type 4 Caribbean 814669 strain21 (M17255), and the related viruses Japanese encephalitis virus22 (M18870, MS5506, D90195), yellow fever virus23 (K02749), and Kunjin virus24 (D00246). We found a region corresponding to nucleotides 10,406 to 10,423 of dengue-1 that is highly conserved in all four serotypes of dengue virus. Within this region, only two base changes were found. In other flaviviruses checked, with maximal alignment, a difference of at least five bases was found. For the sense primer we chose a mixture of the sequence homologous to dengue 1, 3, and 4 (ALD-1: 5'-AAA CCG TGC TGC TAG-3') and the sequence homologous to dengue-2 (ALD-1b: 5'-AAA CTG TGC AGC CTG TAG-3'). For the antisense primer, we selected an oligonucleotide that is complementary to nucleotides 10,617 to 10,634 of dengue-1 (ALD-2: 5'-TCT CTC CCA GCG TCA ATA-3'). This sequence is also conserved in dengue-3. In dengue-2 and dengue-4, there is a single base difference (Figure 1A). In Japanese encephalitis virus and yellow fever virus, there are four and three base mismatches, respectively. Despite the highly conserved nature of our primers, the regions between the primers are quite variable. The sequence identity of the PCR products among the four serotypes of dengue virus ranges between 77% and 90%. The expected sizes of the PCR products are 229 basepairs (bp), 233 bp, 227 bp, and 241 bp for dengue virus types 1, 2, 3, and 4, respectively.

### Reverse transcriptase-polymerase chain reaction

The method we used consists of reverse transcription using the
downstream primer ALD-2, heat inactivation of the reverse transcriptase, and PCR incorporating the upstream primers ALD-1 and ALD-1b. Fourteen microliters of isolated RNA was added to 6 µl of RT mixture solution containing 50 mM KC1, 10 mM Tris-HCl (pH 9.0 at 25°C), 0.1% Triton X-100, 1.0 mM MgCl2, 25 pmol of downstream primer ALD-2, 0.2 mM of each dNTP, 2.0 U of avian myeloblastosis virus (AMV) reverse transcriptase (Promega, Madison, WI), and 4.0 U of RNase inhibitor (Pharmacia). Reverse transcription was carried out at 42°C for 30 min, followed by inactivation of the reverse transcriptase at 95°C for 5 min. Thirty microliters of the PCR mixture was then added to the reaction mixture. The PCR mixture contains 50 mM KC1, 10 mM Tris-HCl (pH 9.0 at 25°C), 0.1% Triton X-100, 1.0 mM MgCl2, 25 pmol of each upstream primer ALD-1 and ALD-1b, 0.2 mM of each dNTP, and 1.25 U of Tth DNA polymerase (Promega). The reaction was carried out at 92°C for 1 min, 53°C for 1 min, and 72°C for 1 min for 10 cycles, and continued at 92°C for 30 sec, 55°C for 30 sec, and 72°C for 30 sec for 30 cycles, followed by incubation at 72°C for 5 min. Fifteen microliters of sample was subjected to 2.2% agarose gel electrophoresis and the gel was then stained with ethidium bromide.

**Viruses.** To optimize the RT-PCR technique and to analyze its sensitivity, we used reference virus strains: dengue virus type 1 Hawaii strain, dengue virus type 2 New Guinea F strain, dengue virus type 3 CH53489 strain, and dengue virus type 4 814669 strain. To evaluate its sensitivity, we used reference virus stocks. We speculated that this band might result from the secondary structure of the 3'-noncoding region products. This method also gave positive results with other laboratory strains of dengue viruses tested, including dengue virus type-1 Mochizuki strain, dengue virus type-2 strains Thai-257 and M11355, dengue virus type 3 strains Sri Lanka-904 and Sri Lanka-969, and dengue virus type 4 strains H241 and Thai-286. Results were negative for West Nile virus, yellow fever virus, Japanese encephalitis virus, and Sindbis virus.

**Preliminary study of plasma specimens from children with acute dengue infection.** In a preliminary study to confirm whether our results with serum spiked with dengue virus also applied to clinical samples, we applied our method to 39 plasma samples from children with dengue fever or dengue hemorrhagic fever. Dengue virus had previously been isolated from these samples by mosquito inoculation. We tested six samples containing dengue-1, 10 samples with dengue-2, six samples with dengue-3, and 16 samples with dengue-4. All the samples had been obtained on the day of clinical presentation, no more than 72 hr after the onset of fever, and from zero to five days before defervescence. Results of PCR analysis are shown in Table 1 by day relative to defervescence. Thirty eight of the 39 samples were positive by RT-PCR. The one negative specimen was obtained from a dengue-2—virus infected patient on the last day of fever. Two samples from healthy persons and one sample from a patient with hepatitis C gave negative results.

**Comparison of RT-PCR and mosquito inoculation for detection of viremia.** To further study the sensitivity and specificity of this RT-PCR method in comparison with the mosquito inoculation method, we tested plasma specimens from 20 subjects known to have dengue viremia, comprising five subjects infected with each of the four serotypes. For each subject, we studied the plasma sample obtained at enrollment (study day 1), the last daily plasma sample that yielded dengue virus by mosquito inoculation (last mosquito inoculation positive), the plasma sample from the next daily bleed (first mosquito inoculation negative), and the convalescent sample (follow-up). In most cases mosquito inoculation was not performed on follow-up plasma specimens because a previous blood specimen was negative for viremia and we assumed that later samples would have been negative if tested. We tested a total of 73 samples from these 20 patients; in some cases the last mosquito inoculation positive
was the same as the study day 1 sample or no blood sample was obtained on the day after the last mosquito inoculation positive sample. As a control group, we selected at random plasma samples obtained at enrollment from 44 study subjects who had no serologic evidence of dengue infection and whose blood samples were negative for dengue viremia by mosquito inoculation. Coded specimens were tested by RT-PCR.

Of the 73 samples obtained from patients with dengue infection, 35 samples were positive by mosquito inoculation, while RT-PCR detected dengue viremia in 38 samples. Thirty-two of the RT-PCR-positive samples were also positive by mosquito inoculation, and six samples were mosquito inoculation negative or not done. Three of 35 samples positive by mosquito inoculation were negative by RT-PCR. Among 44 samples from the febrile nondengue control group, two samples were positive by RT-PCR (Table 2).

Tables 3 and 4 show RT-PCR results for samples from patients with dengue viremia with reference to the time of sample collection. Of 20 samples obtained on the day of presentation, we detected dengue virus in 19 samples by RT-PCR. The one negative sample was obtained from a dengue-2-infected patient two days before defervescence. Of the 20 samples obtained on the last day that yielded dengue virus by RT-PCR in 17 samples, but failed to detect dengue RNA in one sample each of dengue-2, dengue-3, and dengue-4. Of the 18 first mosquito inoculation–negative samples, obtained between two days before and one day after defervescence, we detected dengue virus in two samples that were positive in mosquitoes for dengue-3 and in one sample positive for dengue-4. Of 19 follow-up samples we detected dengue viremia by RT-PCR in one sample from a dengue-1-infected patient obtained four days after defervescence, and in two dengue-2 samples that were obtained five and seven days after defervescence. Results from these samples showed weak bands. Mosquito inoculation assays had not been performed on these specimens.

We repeated RT-PCR on samples that gave discrepant results between RT-PCR and mosquito inoculation. Two follow-up samples (both dengue-2), two first mosquito inoculation–negative samples (both dengue-3), one last mosquito inoculation–positive sample, and two samples from the control group, which were positive by RT-PCR on the first test, were negative on repeat testing. One dengue-3 sample that was negative in the first RT-PCR and positive for mosquito inoculation gave a positive result on the second test.

**DISCUSSION**

We describe an alternative method for a sensitive, rapid, simple and economical RT-PCR procedure for the diagnosis of dengue virus infection. There are several reports describing RT-PCR for the detection of dengue virus using different approaches for the amplification of viral RNA and the detection of the PCR product. The objectives of several of these reports were to detect and determine the serotype of virus strains that had been isolated in mosquitoes or tissue culture. For this purpose, RT-PCR followed by hybridization or nested PCR gave good results. Although the sensitivity was good, these procedures still required considerable time and labor for use in patient management. Morita and others proposed a rapid and simple method using NP-40 and type-specific primers in which RNA isolation, reverse transcription, and PCR were performed on the same day.

### TABLE 1
Comparison of reverse transcriptase–polymerase chain reaction with mosquito inoculation for dengue virus detection in plasma specimens (preliminary study)

<table>
<thead>
<tr>
<th>Dengue serotype</th>
<th>Total</th>
<th>5</th>
<th>4</th>
<th>3</th>
<th>2</th>
<th>1</th>
<th>0</th>
<th>Unknown†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dengue-1</td>
<td>6/6</td>
<td>–</td>
<td>2/2</td>
<td>1/1</td>
<td>2/2</td>
<td>1/1</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Dengue-2</td>
<td>10/11</td>
<td>1/1</td>
<td>2/2</td>
<td>3/3</td>
<td>2/2</td>
<td>2/2</td>
<td>0/1</td>
<td></td>
</tr>
<tr>
<td>Dengue-3</td>
<td>6/6</td>
<td>–</td>
<td>2/2</td>
<td>2/2</td>
<td>1/1</td>
<td>–</td>
<td>1/1</td>
<td></td>
</tr>
<tr>
<td>Dengue-4</td>
<td>16/16</td>
<td>–</td>
<td>–</td>
<td>4/4</td>
<td>8/8</td>
<td>4/4</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>38/39</td>
<td>1/1</td>
<td>4/4</td>
<td>10/10</td>
<td>14/14</td>
<td>8/8</td>
<td>0/1</td>
<td></td>
</tr>
</tbody>
</table>

* The day when the body temperature decreased and remained below 38°C is defined as day zero.
† Subject withdrawn from the study before defervescence.
‡ Acute febrile illness without evidence of acute dengue infection by mosquito inoculation and complete serologic testing.
§ Both showed weak bands and were negative on repeat testing.

### TABLE 2
Comparison of reverse transcriptase–polymerase chain reaction (RT-PCR) with mosquito inoculation for detection of dengue viremia during acute febrile illness

<table>
<thead>
<tr>
<th>Dengue*</th>
<th>Nondengue†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Virus isolation positive</td>
<td>Virus isolation negative</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>RT-PCR positive</td>
<td>32</td>
</tr>
<tr>
<td>RT-PCR negative</td>
<td>3</td>
</tr>
<tr>
<td>Total</td>
<td>35</td>
</tr>
</tbody>
</table>

* Acute febrile dengue virus infection confirmed by mosquito inoculation and serologic testing.
† Acute febrile illness without evidence of acute dengue infection by mosquito inoculation and complete serologic testing.
‡ Five of these showed weak bands and were negative on repeat testing.
§ Both showed weak bands and were negative on repeat testing.

### TABLE 3
Reverse transcriptase-polymerase chain reaction (RT-PCR) positivity of plasma from patients infected with dengue virus

<table>
<thead>
<tr>
<th>Virus</th>
<th>Day 1</th>
<th>Last MI+*</th>
<th>1st MI†</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dengue-1</td>
<td>5/5</td>
<td>4/5</td>
<td>0/5</td>
<td>1/5</td>
</tr>
<tr>
<td>Dengue-2</td>
<td>4/5</td>
<td>4/5†</td>
<td>0/4</td>
<td>2/5</td>
</tr>
<tr>
<td>Dengue-3</td>
<td>5/5</td>
<td>4/5</td>
<td>2/4</td>
<td>0/4</td>
</tr>
<tr>
<td>Dengue-4</td>
<td>5/5</td>
<td>5/5†</td>
<td>1/5</td>
<td>0/5</td>
</tr>
<tr>
<td>Total</td>
<td>19/20</td>
<td>17/20</td>
<td>3/18</td>
<td>3/19</td>
</tr>
</tbody>
</table>

* The last daily plasma sample that yielded dengue virus by mosquito inoculation (MI).
† The first daily plasma sample that was negative for dengue virus by mosquito inoculation.
‡ One of these samples was a first day sample.
Detection of dengue virus by mosquito inoculation (MI) and reverse transcriptase–polymerase chain reaction (RT-PCR) during the course of illness*

<table>
<thead>
<tr>
<th>Fever day†</th>
<th>MI+</th>
<th>PCR+</th>
<th>MI+</th>
<th>PCR+</th>
<th>MI+</th>
<th>PCR+</th>
<th>MI+</th>
<th>PCR+</th>
</tr>
</thead>
<tbody>
<tr>
<td>−7 to −4</td>
<td>2/2</td>
<td>2/2</td>
<td>2/2</td>
<td>2/2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>−3 to −1</td>
<td>25/30</td>
<td>24/30</td>
<td>6/7</td>
<td>6/7</td>
<td>7/8</td>
<td>6/8</td>
<td>4/5</td>
<td>4/5</td>
</tr>
<tr>
<td>0</td>
<td>5/14</td>
<td>4/14</td>
<td>2/5</td>
<td>1/5</td>
<td>1/3</td>
<td>1/3</td>
<td>2/2</td>
<td>1/2</td>
</tr>
<tr>
<td>1 to 3</td>
<td>1/7</td>
<td>2/7</td>
<td>0/2</td>
<td>0/2</td>
<td>1/2</td>
<td>1/2</td>
<td>0/2</td>
<td>1/2</td>
</tr>
<tr>
<td>4 to 8</td>
<td>0/17</td>
<td>3/17</td>
<td>0/4</td>
<td>1/4</td>
<td>0/5</td>
<td>2/5</td>
<td>0/4</td>
<td>0/4</td>
</tr>
<tr>
<td>Unknown</td>
<td>2/3</td>
<td>3/3</td>
<td>−</td>
<td>−</td>
<td>2/5</td>
<td>2/5</td>
<td>0/4</td>
<td>0/4</td>
</tr>
<tr>
<td>Total</td>
<td>35/73</td>
<td>38/73</td>
<td>10/20</td>
<td>10/20</td>
<td>9/18</td>
<td>10/18</td>
<td>8/16</td>
<td>9/16</td>
</tr>
</tbody>
</table>

* Number of samples positive/number tested.
† Relative to day of defervescence.

The procedure we describe in this report can rapidly indicate whether or not an acutely febrile patient is infected with dengue virus, which is critical for patient management. In the preliminary experiment, we applied our method to plasma specimens obtained on the day of presentation to the outpatient clinic, no more than 72 hr after the onset of fever. Dengue virus had been isolated from these specimens by mosquito inoculation. We could detect dengue RNA in 38 of these 39 samples. The only sample that was negative by PCR but positive by mosquito inoculation was obtained on the last day of fever. In the subsequent study done on serial plasma specimens obtained from children with acute febrile illness, RT-PCR detected dengue virus in 34.2% of the samples, while mosquito inoculation detected dengue virus in 29.9%. Compared with mosquito inoculation, the overall sensitivity of the RT-PCR is 91.4% (32 of 35; 95% confidence interval [CI] = 82.2–100%). For the samples obtained at the time of clinical presentation, which are the most important for clinical use, this method showed a sensitivity of 95.0% (19 of 20; 95% CI = 85.5–100%).

All first day samples and 15 of the 17 later specimens that were positive by both RT-PCR and mosquito inoculation showed a strong, distinctive band, while the two false-positive RT-PCR specimens were seen as weak bands and were negative on repeat testing. Samples obtained later in the course of acute dengue infection that were positive by RT-PCR but negative by mosquito inoculation showed weak bands, and five of six such samples were RT-PCR negative on repeat testing. This result agrees with the observations made by Gubler and others27 and Chan and others5 that samples for either virus isolation or RT-PCR should ideally be obtained in early phase of illness. These findings may reflect a low virus titer in the plasma in the later stages of illness. Gubler and others reported the presence of dengue virus at low titer in patient serum as late as 12 days after the onset of illness using the mosquito inoculation technique.27

The RT-PCR method we used had a specificity of 95.4%. It is difficult to compare this result with other published methods since none of the earlier reports on dengue RT-PCR analyzed a large number of samples from patients with suspected dengue virus infection with complete serologic tests as negative controls. A possibility that cannot be overlooked is carry-over contamination; however, we exercised precautions to prevent carry-over contamination, such as the use of several samples without RNA as controls in each run, physical separation of pre- and post-PCR manipulations, and the use of aerosol-barrier pipettes.

Several investigators have reported single-step RT-PCR methods for detecting dengue virus6,9,11,13 by using different sources of RT and DNA polymerase. We tried several methods using RT-AMV (Promega) and T7h DNA polymerase (Promega), using rTth DNA polymerase (Perkin Elmer, Foster City, CA), and the Access RT-PCR® system (Promega) containing RT-AMV and Thermus flavus (T7f) DNA polymerase. We found the first two methods to be less sensitive than our method. Chang and others6 and Lanciotti and others8 improved the sensitivity of their single-step RT-PCR by ELISA or nested PCR, respectively. Since our objective is to learn whether or not a patient is having dengue viremia on the same day, we chose to continue using the conventional two-step RT-PCR and staining of DNA bands in agarose gels with ethidium bromide. Recently, we found that the Access RT-PCR® system gave a comparable sensitivity with our method for detecting viral RNA in serum spiked with dengue virus.

It is often difficult to clinically identify children with dengue until defervescence. This rapid diagnostic assay, although not superior to the mosquito inoculation technique in sensitivity, should be helpful in the rapid identification of patients with dengue in the outpatient setting early in the course of disease and useful in the early management of children with the disease.
Acknowledgments: We thank Drs. Walter E. Brandt, Kenneth Eckels, Bruce L. Innis, Jack McCown, Jacob J. Schlesinger, and Margo A. Brinton for providing reference viruses; and Dr. Rebeca Rico-Hesse for providing Japanese encephalitis viral RNA. We also thank Drs. Suchittra Nimmanittaya, Saroj Sunyakom, Narongchai Kunentrasi, Suntaree Ratanachauke, Wiboon Vimarititchai, Supaporn Kiattapolpoj, the pediatricians who carried out the clinical studies; Nonglak Ongsakorn, Sanguan Boonak, Naoyubol Nutkumhang, and Sontakle Linmp for virus isolation and identification; Panor Srisongkram, Ming Choohong, Piyanard Chuasuwan, and Chandana Limsomwong for technical assistance; as well as the Armed Forces Research Institute of Medical Sciences research nurses, technicians in blood processing, and patients who participated in this study.

Financial support: This publication was made possible by grant number PO1-Al-34533 from the National Institutes of Health (NIH) and support from the U.S. Army Medical Research and Materiel Command.

Disclaimer: The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or the Department of Defense.

Authors’ addresses: T. Mirawati Sudiro, Hiroaki Ishiko, Sharone Green, Alan L. Rothman, Jurand Janus, Ichiro Kurane, and Francis E. Ennis, Division of Infectious Diseases and Immunology, University of Massachusetts Medical Center, 55 Lake Avenue North, Worcester, MA 01655. David W. Vaughn, Ananda Nisalak, and Boonyos Raengsakulrach, Department of Virology, U.S. Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand. Siripen Kalayanarooj, Department of Infectious Disease, Bangkok Children’s Hospital, Bangkok, Thailand.

Reprint requests: T. Mirawati Sudiro, Division of Infectious Diseases and Immunology, University of Massachusetts Medical Center, 55 Lake Avenue North, Worcester, MA 01655.

REFERENCES


